Impact of Immunotherapy on Bladder Cancer

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Three additional clinical trials will study nadofaragene firadenovec-vncg for the treatment of patients with non-muscle invasive bladder cancer.

An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.